{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dysmenorrhoea/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"4df0c333-cd3d-5a3c-afe4-0ae5fc002512","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 5a923648-c422-4ec4-8fd0-58c9f5ae7603 --><h2>Changes</h2><!-- end field 5a923648-c422-4ec4-8fd0-58c9f5ae7603 -->","summary":null,"htmlStringContent":"<!-- begin item 0d2590dc-7336-4af6-9e48-787a098d9955 --><!-- begin field e0576299-f37e-4fbc-80a7-9f4d3923d0be --><p><strong>November 2018</strong><strong> </strong>— reviewed. A literature search was conducted in November 2018 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. No major changes to clinical recommendations have been made, but the topic has been restructured.</p><!-- end field e0576299-f37e-4fbc-80a7-9f4d3923d0be --><!-- end item 0d2590dc-7336-4af6-9e48-787a098d9955 -->","topic":{"id":"0c7e1674-25ac-5412-81b0-d4d1ca0a6532","topicId":"d2202fa1-429e-4011-8135-3a2049c1d520","topicName":"Dysmenorrhoea","slug":"dysmenorrhoea","lastRevised":"Last revised in November 2018","chapters":[{"id":"f2974ab7-c383-5709-9194-8c1347a6e48d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"44579560-9fd2-537d-9b92-1eabb7a6143a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"663ab4e7-a158-568e-aec2-f7126771c014","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4df0c333-cd3d-5a3c-afe4-0ae5fc002512","slug":"changes","fullItemName":"Changes"},{"id":"0cf82f0d-38d8-5014-b235-85ebadfd605b","slug":"update","fullItemName":"Update"}]},{"id":"0dbf2666-492f-549f-b313-71b596cc0bcb","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"658bff21-3654-5661-a3d2-b5876b69d66d","slug":"goals","fullItemName":"Goals"},{"id":"0462643f-eace-5cb8-bd65-a2ad2a6bc503","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f79c04ce-6e9e-530e-abe1-732f51abe4f9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"966786c7-9c68-51d3-a65e-f510e133e935","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"99ca2fb4-b9f3-55f3-b3fc-2cb3a6140ca3","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"6f279400-7735-5332-860b-65383f816269","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"1240ce42-fa9b-587f-a779-df6cfaa6437e","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"470bee4d-280f-5695-9518-a1cef26ab7db","slug":"definition","fullItemName":"Definition"},{"id":"41df263c-252d-5f94-a7e5-7075a706ca73","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9064c3fa-918a-59ee-82c8-1b64076bea3a","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"111560c2-8bc9-57c8-83a3-14a4bc9cb537","slug":"impact","fullItemName":"Impact"}]},{"id":"31c4642b-d290-511c-876a-b3c9bf5c05e8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"9e57c91b-71e7-5b04-8caf-81fe28fb3138","slug":"assessment","fullItemName":"Assessment"}]},{"id":"082477b9-8adf-57e4-91b7-7aba32969c6f","fullItemName":"Management","slug":"management","subChapters":[{"id":"27fbeb95-a0df-5d64-8bd8-27370c30f372","slug":"primary-dysmenorrhoea","fullItemName":"Scenario: Primary dysmenorrhoea"},{"id":"43361bbb-ae8f-5ca6-8454-2e8e5549c99f","slug":"secondary-dysmenorrhoea","fullItemName":"Scenario: Secondary dysmenorrhoea"}]},{"id":"671cbd64-2abc-53b7-8042-656007db062e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d51cf8f7-55d4-59bd-a4f8-37d09e71d89f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"acb9d93f-df11-56e0-aa31-f4174fae9d24","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c7e3ba8a-24a7-5158-9416-9c5f71bdd035","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"95e6d539-0c3a-5a89-a916-8b5b5a90ff4c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"9e6affac-20d1-5beb-9283-787dccb74b65","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"188722b3-3b43-511c-a127-6e20de2faca2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c3438447-13a8-5fc3-8f6e-692e576f9959","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"663ab4e7-a158-568e-aec2-f7126771c014","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"07900cad-e63d-5c20-ac0b-707a04bdb240","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 613ca355-ca36-4739-9f92-f1661c48b47e --><h3>Previous changes</h3><!-- end field 613ca355-ca36-4739-9f92-f1661c48b47e -->","summary":null,"htmlStringContent":"<!-- begin item 5f474dca-c03b-4147-ba1e-04ef83c07709 --><!-- begin field 38e3de4f-f983-45ef-a20f-56123c42d8ae --><p><strong>March to May 2014</strong> — reviewed. Literature searches were conducted in January 2014 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of this topic. Only one significant change has been made to this topic:</p><ul><li>Codeine has been removed as a treatment option. There is no evidence that weak opioids are effective for the treatment of primary dysmenorrhoea. Expert opinion published in guidelines by the European Association of Urology state that as a result of the chronic nature of dysmenorrhoea, potentially addictive analgesics should be avoided [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dysmenorrhoea/references/\">Engeler et al, 2012</a>]. This is in line with recommendations made by the Royal College of Obstetricians and Gynaecologists [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dysmenorrhoea/references/\">RCOG, 2012</a>].</li></ul><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>May 2011 </strong>— minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>October 2010 </strong>— minor update. From mid-October 2010, Nexplanon<sup>® </sup>will replace Implanon<sup>®</sup>. Nexplanon<sup>® </sup>is bioequivalent to Implanon<sup>®</sup>. The main differences are that Nexplanon<sup>® </sup>is radio-opaque and the insertion technique is different. Issued in October 2010.</p><p><strong>September 2010 </strong>— minor update. A prescription for Rigevidon<sup>®</sup>, a new ethinylestradiol plus levonorgestrel combined oral contraceptive (COC) pill, has been added. Issued in September 2010.</p><p><strong>June 2010 </strong>— minor update. A prescription for Levest<sup>®</sup>, a new ethinylestradiol plus levonorgestrel COC pill, has been added. Issued in June 2010.</p><p><strong>March 2010 </strong>— minor update. Results of the updated Cochrane systematic review on nonsteroidal anti-inflammatory drugs for dysmenorrhoea have been updated in the <em>Supporting evidence</em> section. Issued in March 2010.</p><p><strong>June 2009 </strong>— minor update. Correction to prescription title. Issued in June 2009.</p><p><strong>December 2008 to March 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. Progestogen-only contraceptives are now recommended as an alternative to COCs.</p><p><strong>February 2009 </strong>— minor update. The upper age limit on the COC pill prescriptions has been reduced to 50 years. Issued in March 2009.</p><p><strong>October 2006 </strong>— minor update. Analgesia prescriptions have been updated to reflect new doses of ibuprofen for children as recommended in the British National Formulary (BNF). Issued in October 2006.</p><p><strong>October to December 2005 </strong>— reviewed. Validated in March 2006 and issued in May 2006.</p><p>This guidance has been reviewed and updated following a full literature review. There have been no major changes to the recommendations. A more detailed Supporting evidence section has been included.</p><p><strong>August 2002</strong> — reviewed. Validated in December 2002 and issued in February 2003.</p><p><strong>November 1999 </strong>— written. Validated in March 2000 and issued in May 2000.</p><!-- end field 38e3de4f-f983-45ef-a20f-56123c42d8ae --><!-- end item 5f474dca-c03b-4147-ba1e-04ef83c07709 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}